Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

66 results about "Diabetes in pregnancy" patented technology

Gip analog and hybrid polypeptides with selectable properties

InactiveUS20090036364A1Increased insulin secretionDecreasing bone loss boneSenses disorderNervous disorderDyslipidemiaPhysiology
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Synthetic apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG

Hybrid Polypeptides with Selectable Properties

InactiveUS20090286723A1Reverse glucose intoleranceIncrease massSenses disorderPeptide/protein ingredientsBlood lipidsEating disorders
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Synthetic apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG

Synthetic linear apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG

Gip analog and hybrid polypeptides with selectable properties

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP +1

Methods and compositions for treating diabetes mellitis

Methods for modulating diabetes, impaired glucose tolerance, gestational diabetes and glucose resistance in a mammal, particularly a human. In one embodiment the method comprises administering a gallotannin composition to a mammal in need of the same. The gallotannin composition comprises one or more select hydrolysable gallotannins. In another embodiment the method comprises administering a gallotannin variant composition comprising one ore more select gallotannin variant compounds to the subject. Methods of preventing or treating weight gain in a subject. The method comprises administering the gallotannin composition of the present invention, the gallotannin variant composition of the present invention, or a combination of the gallotannin composition of the present invention and the gallotannin variant composition of the present invention to the subject. The present invention also relates a gallotannin variant compound or a salt thereof, and a pharmaceutical composition comprising such compound or the salt thereof.
Owner:OHIO UNIV

Protein markers of gestational diabetes mellitus in urine and use in early diagnosis

ActiveCN110286234AReduce the phenomenon of inhibitionRestricted FeaturesComponent separationMass spectrometric analysisProtein markersBacteriuria
The present invention relates to protein markers of gestational diabetes mellitus in urine and the use in early diagnosis. In particular, the present invention relates to the use of an identification reagent selected from the following proteins for preparing reagents for early diagnosis of gestational diabetes mellitus: protein NOV homolog, Peroxiredoxin-5 (PRDX-5), Hepatocyte growth factor-like protein (HFGL) and the combination thereof. The protein NOV homolog, the Peroxiredoxin-5 and the Hepatocyte growth factor-like protein and the combination thereof have good clinical application prospects for early diagnosis of gestational diabetes mellitus.
Owner:安肽和(杭州)医疗科技有限公司

Composition for use in increasing insulin sensitivity and/or reducing insulin resistance

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and / or reducing insulin resistance. This composition optionally further comprises 2′-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and / or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and / or type II diabetes.
Owner:SOC DES PROD NESTLE SA

Vitamin B2 for gestational diabetes

The present invention relates to a maternal nutrition composition comprising myo-inositol and vitamin B2. Such a composition has been specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman and / or to a lactating woman. The present invention also relates to vitamin B2 for use to treat or prevent gestational diabetes mellitus and a condition associated therewith in a pregnant subject or its offspring, wherein said vitamin B2 is administered to said subject before and / or during pregnancy and / or during lactation.
Owner:SOC DES PROD NESTLE SA

Special medical-purpose emulsion for relieving diabetic symptoms and preparation method of special medical-purpose emulsion

The invention discloses a special medical-purpose emulsion for relieving diabetic symptoms and a preparation method of the special medical-purpose emulsion. Each liter of the emulsion comprises the following components: 45-80 g of a low-glycemic-index carbohydrate composition, 20-60 g of high-quality protein, 20-60 g of vegetable oil, 50-100 g of malt paste, 0.2-1.0 g of compound vitamins, 0.2-1.0 g of compound minerals, 1-12 g of an emulsifier and 1-5 g of a stabilizer. The special medical-purpose emulsion contains controlled-release carbohydrate, and after compounding is finished, the GI value of the final product is 30-55. The ratio of animal protein to vegetable protein is 2.5:1.5, the branched chain amino acid composition and content are high, and insulin release can be promoted. The mass of medium-chain fatty acid accounts for more than 50% of the total fat content, the emulsion has comprehensive and balanced nutrition, and the product system is high in stability. The special medical-purpose formulated emulsion is suitable for people with diabetes and hyperglycemia symptoms, especially for being used by patients with gestational diabetes mellitus as diet replacement or nutritional supplement, is wide in application range and convenient to use, and also has the effects of promoting lactation, optimizing milk and improving milk quality when used after childbirth.
Owner:XIAN LI BANG CLINICAL NUTRITION CO LTD

Enteral nutrition preparation for women with gestational diabetes, and preparation method and use thereof

The invention belongs to the field of food production, and particularly relates to an enteral nutrition preparation for women with gestational diabetes, and a preparation technology thereof. The enteral nutrition preparation comprises the following raw materials: marine animal protein or soybean peptide, laminarin, enzymatic hydrolysis powder of turtle meat, olive oil or tea-seed oil. In addition, the enteral nutrition preparation also contains active probiotics, amino acids, a calcium preparation and fruit and vegetable powder, wherein the dosage form of the enteral nutrition preparation is powder or emulsion. The invention simultaneously discloses a preparation method of two dosage forms of the nutrition preparation. Special pharmacological bioactive substances and nutrient function materials are reasonably compounded aiming at the pathological and physical characteristics of the women with gestational diabetes, and special nutrient requirements and metabolism requirements of infants and mothers, so as to enhance the effects of effective components; comprehensive and balanced nutrition is provided for the women with gestational diabetes; the body immune function is enhanced; the pregnancy reaction is reduced; the gestational diabetes are prevented; blood sugar is reduced in an assisting manner; the nutrition and the health of the infants and mothers for the women with gestational diabetes are well ensured.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Application of biomarker in preparation of gestational diabetes diagnostic reagent

The invention relates to the field of medical diagnosis, in particular to biomarkers which are screened by metabonomics and are used for identifying and diagnosing gestational diabetes mellitus, and a model which is used for diagnosing whether a gestational individual is diabetes mellitus or not is established according to the biomarkers. The invention provides a biomarker and a diagnostic model for differential diagnosis of gestational diabetes mellitus, which can be applied to early diagnosis or prediction of gestational diabetes mellitus and have important significance in prevention or treatment of gestational diabetes mellitus.
Owner:杭州凯莱谱精准医疗检测技术有限公司

In vitro method for identifying a pregnancy related disease

ActiveUS20180259534A1Strong and cost-effective methodHigh sensitivityMetabolism disorderDisease diagnosisDisease riskGynecology
The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.
Owner:UNIV DE LOS ANDES

Application of substance for detecting oral bacteria to diagnosis of gestational diabetes mellitus

The invention discloses an application of a substance for detecting oral bacteria to diagnosis of gestational diabetes mellitus. The substance for detecting the oral bacteria disclosed by the invention is a substance for detecting Streptococcus, Veillonella, Lautropia and / or Neisseria in saliva and / or dental plaque. According to the invention, the inventor finds that the Streptococcus, the Veillonella, the Lautropia and / or the Neisseria in the oral cavity can be used for detecting the gestational diabetes mellitus, and the accuracy can reach 74.41%-82.72% (P< 0.05 and FDR<0.1). The sampling for judging the gestational diabetes mellitus by utilizing microorganisms in the oral cavity is convenient, rapid and safe, and has non-invasiveness, and the substance can be used as an effective tool for auxiliary diagnosis, detection and prevention of the gestational diabetes mellitus in clinical and daily pregnancy health care.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Novel marker for gestational diabetes

The present invention relates to methods of typing a female subject as being at risk of developing gestational diabetes, comprising determining a level of expression of Secreted Frizzled-Related Protein 4 (sFRP4). The invention further relates to methods of treating of a subject being at risk of developing, gestational diabetes, comprising typing the subject according to the methods of the invention, and treating the subject with a dietary meal plan and / or physical activity. The invention additionally relates to kit for a pregnant female subject for susceptibility to gestational diabetes, use of a kit according to the invention for typing a female subject as being at risk of developing gestational diabetes, and to an antibody specific to sFRP4 for use in a method for determining a risk of a female subject of developing gestational diabetes.
Owner:IQ PROD

Formula of food therapy capable of recuperating gestational diabetes and preparation method of formula

The invention relates to a formula of a food therapy capable of recuperating gestational diabetes and a preparation method of the formula. The formula comprises haws, Chinese wolfberry root-bark, radix trichosanthis, polished round-grained rice, maize flour and table salt. The preparation method of the formula comprises the following steps: (1) cleaning the Chinese wolfberry root-bark and the radix trichosanthis with clean water, adding water which is 3-5 times of the raw materials, decocting the Chinese wolfberry root-bark, the radix trichosanthis and the water twice, and filtering off liquid medicines; (2) cleaning the polished round-grained rice, shelling the haws, adding the liquid medicines, adding clean water which is one time of the raw materials, and cooking the polished round-grained rice, the shelled haws and the clean water until the rice is boiled out; (3) adding the maize flour, so that the porridge is made into thin paste; and (4) adding the table salt, and uniformly stirring the thin paste and the table salt so as to obtain the food which can be eaten. The formula of the food therapy capable of recuperating gestational diabetes and the preparation method of the formula, disclosed by the invention, are simple and easy to operate, wide in sources of the raw materials, notable in effect, safe, and free from toxic and side effects.
Owner:庞锦霞

Nutritional diet management map creating method and device based on gestation period

The invention provides a nutritional diet management map creation method and device based on a gestational period. The method comprises the following steps: acquiring target structured data and target unstructured data related to gestational diabetes mellitus; based on the target structured data, determining symptoms of the gestational diabetes mellitus and nutritional diet information having an association relationship with the symptoms, and based on the symptoms and the nutritional diet information, creating a nutritional diet management map ontology in the gestational period; identifying a target entity relationship matched with the symptom and / or the nutritional diet information in the target unstructured data; and carrying out fusion processing on the nutritional diet management map body and the target entity relationship to generate the gestational diabetes mellitus nutritional diet management map. According to the invention, visual and systematic scientific diet guidance can be provided for the pregnant user in a targeted manner, and the acquisition cost of the nutritional diet scheme is reduced, so that the management effect of the nutritional diet in the gestation period is greatly improved.
Owner:TSINGHUA UNIV +1

A kind of enteral nutrition preparation for women with gestational diabetes mellitus and preparation method and use thereof

The invention belongs to the field of food production, and in particular relates to an enteral nutrition preparation suitable for women with gestational diabetes and its preparation process. The raw materials include: marine animal protein or soybean peptide, laminarin, turtle meat enzymatic hydrolysis powder, olive oil Or tea seed oil, in addition, it also contains active probiotics, amino acids, calcium preparations and fruit and vegetable powder. Its dosage form is powder or emulsion. The invention simultaneously discloses the preparation methods of the two dosage forms of the nutritional preparation. According to the pathological and physical characteristics of women with gestational diabetes and the special nutritional and metabolic needs of mothers and infants, the present invention adopts special pharmacologically active substances and nutritional functional substances for reasonable compounding, enhances the effect of active ingredients, and provides comprehensive health benefits for mothers and infants of women with gestational diabetes. Balanced nutrition can enhance the immune function of the body, reduce pregnancy reactions, prevent the occurrence of gestational diabetes and assist in lowering blood sugar, so as to better ensure the nutrition and health of mothers and infants of women with gestational diabetes.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Health management method and device for gestational diabetes mellitus and electronic equipment

The invention provides a health management method and device for gestational diabetes mellitus and electronic equipment, and the method comprises the steps: obtaining the personal basic information and exercise taboo information of a target user; and pushing a diet catering scheme and a pregnancy exercise strategy to the target user based on the personal basic information and the exercise taboo information. According to the method, the diet catering scheme and the pregnancy exercise strategy can be pushed to the target user in a manner of interacting with the target user, so that the purpose of active health management of the target user is achieved, timely professional diet guidance and professional exercise guidance are provided for the target user, the probability of occurrence of complications of gestational diabetes patients is greatly reduced, and the experience of the gestational diabetes patients is improved. The pregnancy outcome of a gestational diabetes patient is improved, and the prevention effect on gestational diabetes is improved.
Owner:TSINGHUA UNIV +1

Methods and reagents for the assessment of gestational diabetes

The invention involves assays, diagnostics, kits, and assay components for determining levels of glycated CD59 in the assessment of gestational diabetes mellitus and / or related disorders and / or conditions. Some kits comprise a capture antibody capable of associating with a capture epitope on CD59, wherein said capture epitope may lack lysine residue number 41 (K41 ). Kits may also comprise a detection antibody capable of associating with a detection epitope on CD59. Such detection epitopes may comprise glycated K41.
Owner:哈佛大学董事会

Probiotic-flavored fermented milk without cane sugar and sweetening agent and preparation method of probiotic-flavored fermented milk

The invention discloses probiotic flavored fermented milk without cane sugar and sweetening agent. The probiotic flavored fermented milk comprises the following components in percentage by weight: 4.0-15.0% of fruit juice, 0.001-0.006% of leavening agent and the balance of raw milk, wherein the total weight percentage of the raw milk is 100%. The invention also discloses a preparation method of the probiotic-flavored fermented milk without sucrose and sweetening agent. By adjusting the formula and not additionally adding cane sugar or a sweetening agent, the product is natural in sweetness and free of bitterness, the immune system of children can be effectively adjusted, and the risk of infant eczema and gestational diabetes mellitus is reduced. Meanwhile, a conventional fermented milk production process is optimized, and a low-temperature stirring and mixing method is adopted, so that the energy consumption is effectively reduced, the high-temperature time of the materials is shortened, and excessive propagation of harmful bacteria is avoided.
Owner:BRIGHT DAIRY & FOOD

Application of urine IGKC protein and polypeptide fragment thereof in normal pregnancy or gestational diabetes

The invention provides an application of a urine immunoglobulin kappa constant region (IGKC) and a polypeptide fragment of the IGKC, and particularly relates to an application of a urine IGKC protein and a polypeptide fragment of the IGKC protein in preparation of a preparation for monitoring normal pregnancy or gestational diabetes mellitus. Researches prove that compared with a normal childbearing age woman group (normal control), the expression of IGKC and polypeptide fragments thereof in normal pregnancy and gestational diabetes mellitus groups is increased, and the IGKC and polypeptide fragments thereof can be used for monitoring and auxiliary diagnosis of gestational state or gestational diabetes mellitus patients. According to the invention, the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and the urine IGKC protein and the polypeptide fragment thereof are detected by using the urine sample.
Owner:张曼

Preparation of double-index immunochromatography kit for detecting Adipo and SHBG

The invention belongs to the field of immunodetection, and particularly relates to a double-index immunochromatography kit for detecting adiponectin (Adipo) and sex hormone binding globulin (SHBG). The main component is an immunochromatography test strip, and the immunochromatography test strip is formed by sequentially pasting a sample pad, a binding pad, a nitrocellulose membrane and absorbent paper on a PVC base plate. Adipo antibody-microspheres and SHBG antibody-microspheres are adsorbed on the binding pad, an Adipo antibody is fixed on the nitrocellulose membrane to form a detection line 1 (T1 line), an SHBG antibody is fixed on the nitrocellulose membrane to form a detection line 2 (T2 line), and an anti-IgG antibody is fixed to form a quality control line (C line). The invention also discloses a process for coupling the Adipo antibody and the SHBG antibody with the microspheres. The Adipo / SHBG detection immunochromatography kit is used to determine the Adipo and SHBG concentrations in blood or other body fluids, and is used for early prediction of insulin resistance, type 2 diabetes mellitus and gestational diabetes mellitus occurrence risks.
Owner:武汉市朗典精医生物科技有限公司

Application of baicalin in the preparation of drugs for preventing neural tube defects in fetuses with gestational diabetes mellitus

The invention provides application of baicalin in preparation of a drug for treating a fetal neural tube defect caused by gestational diabetes mellitus. Based on a model of a fetus with gestational diabetes mellitus, which is established by a chick embryo, a chick embryo experiment is performed by adopting a traditional Chinese medicine monomer baicalin, a result shows that a certain concentrationof baicalin can be used for effectively relieving the neural tube defect induced by a high glucose environment and effectively relieving poor neural tube cell differentiation, elevation of the levelof homocysteine, reduction of the level of retinoic acid and inhibition on self-renewing of neural stem cells caused by the high glucose environment. According to the application, the application range of the baicalin is enlarged, the application value of the baicalin is improved, and the development of new drugs can be further facilitated, for example, the activity of the baicalin is hopefully improved, or the side effect of the baicalin is reduced by structural modification or transformation by taking the baicalin as a lead compound; the safety drug is provided for preventing the neural tubedefect of the fetus with gestational diabetes mellitus, therefore, the application has good application prospect.
Owner:JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products